IWM
ABUS icon

IHT Wealth Management’s Arbutus Biopharma ABUS Stock Holding History

IHT Wealth Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,000
Closed -$45K – 803
2021
Q2 		$45K Hold
15,000
– – ﹤0.01% 928
2021
Q1 		$50K Buy
15,000
+5,000
+50% +$19.3K ﹤0.01% 822
2020
Q4 		$36K Hold
10,000
– – ﹤0.01% 738
2020
Q3 		$31K Buy
+10,000
New +$30.4K ﹤0.01% 656

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

IHT Wealth Management's ABUS Position: Q3 2021 in Review

IHT Wealth Management sold out of Arbutus Biopharma (ABUS) in Q3 2021, closing a stake of 15,000 shares — an estimated $45K sold.

IHT Wealth Management first reported a position in ABUS in Q3 2020 and held it in 4 quarters. The position peaked at $50K in Q1 2021. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2021.

  • IHT Wealth Management reported no remaining Arbutus Biopharma position as of Q3 2021 after selling out during the quarter.
  • IHT Wealth Management sold 15,000 Arbutus Biopharma shares in Q3 2021, an estimated $45K.
  • IHT Wealth Management first reported a position in Arbutus Biopharma in Q3 2020 and held it in 4 quarters.
  • IHT Wealth Management's Arbutus Biopharma position peaked at $50K in Q1 2021.
  • 99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2021.

Based on IHT Wealth Management's 13F filing for Q3 2021, filed 15 Nov 2021.